Beyond T2D and weight management in individuals with overweight or obesity, GLP-1 receptor agonists are approved for metabolic dysfunction associated steatohepatitis in people with moderate or advanced fibrosis, obstructive sleep apnea in obese adults, reduction of major adverse cardiovascular events in adults with T2D and cardiovascular disease (CVD), and slowing progression of chronic kidney disease and cardiovascular mortality in adults with both chronic kidney disease and T2D
By selectively expressing specific genes, GLP-1 analogues with improved properties (such as longer half-life or enhanced biological activity) can be produced
Angptl4 was added at 2.7 g/mL (for a final dose of 200 ng/well) to decrease LPL activity in each LPL source (i.e., HR, bLPL, or PHP) and incubated for 15 min at RT along with a control
Our dedicated medical team specializes in the latest weight loss treatments, including GLP-1 receptor agonists
10.1016/j.jnutbio.2022.109215 59 ZhangY.TanL.LiC.WuH.RanD.ZhangZ
Cells were incubated with the fluorescent probe (FITC)-labeled peptides at different concentrations for 4 h with minimal cytotoxicity (Figure 3A)
